GCTK on Nasdaq

Glucotrack, Inc.

Chief Executive Officer and intends to develop the technology to address the growing Type 1 and Type 2 diabetes market.⁴ From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with FAMILY OFFICE OF AMERICA, INC., Bluejay Diagnostics, Inc. or QTREX Quantum Ltd., or pick any stock.

TickerGCTK on Nasdaq²
IndustrySurgical & Medical Instruments & Apparatus²
HeadquartersAshkelon, Israel²
Incorporated inDE³
Business address301 Rt 17 North, Suite 800, Rutherford, Nj 07070³
Filer categoryNon-accelerated filer, Smaller reporting company³
Legal formCorporation²
LEI549300FJ98RZ4G4ULL57²
StatusActive²
LEI statusLapsed (not renewed)²
Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States²
Registered withDivision of Corporations, Department of State, 4824917²

See how the biggest companies compare on our leaderboards

Chief Executive Officer and intends to develop the technology to address the growing Type 1 and Type 2 diabetes market.⁴ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

1685.6%Operating margin⁵

1690.4%Net margin⁵

-$3.9MFree cash flow⁵

Where the money goes

Where each dollar of revenue went, fiscal 2019

Research and developmentProfit

Research and development31¢$1.6M
Profit69¢$3.5M

Out of $208.0K in revenue.⁵

Financial statements

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Research and development expenses	$9.8M	$9.5M
General and administrative expenses	$6.3M	$5.0M
Total operating expenses	$16.1M	$14.5M
Loss from operations	$16.1M	$14.5M
Other (income) expense	-$26.0K	-$14.0K
Change in fair value of derivative liability	$3.3M	$798.0K
Loss on equity issuance		$1.9M
Loss on settlement of liabilities		$4.8M
Finance expense, net	$57.0K	$583.0K
Total other income	$3.3M	$8.1M
Net loss	$19.4M	$22.6M
Foreign currency translation adjustment	-$49.0K	-$24.0K
Comprehensive loss	$19.3M	$22.6M
Basic loss per share	$31.22	$4,106.00
Diluted loss per share	$31.22	$4,106.00
Weighted average number of common stock outstanding used in computing basic net loss per share	621.1K shares	5.5K shares
Weighted average number of common stock outstanding used in computing diluted net loss per share	621.1K shares	5.5K shares

Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.⁸

Period ending	2025-12-31	2025-01-31	2024-12-31	2024-10-31	2023-12-31
Cash and cash equivalents	$7.4M		$5.6M
Other current assets	$284.0K		$151.0K
Total current assets	$7.7M		$5.8M
Operating lease right-of-use asset, net	$33.0K		$59.0K
Property and equipment, net	$138.0K		$95.0K
Restricted cash			$10.0K
TOTAL ASSETS	$7.8M		$5.9M
Accounts payable	$1.3M		$992.0K
Operating lease liability, current	$28.0K		$26.0K
Promissory notes	$3.2M
Convertible promissory notes			$5.0K
Other current liabilities	$246.0K		$252.0K
Total current liabilities	$4.8M		$1.3M
Derivative financial liabilities	$1.0K		$17.4M	$16.6M
Operating lease liability, non-current	$5.0K		$33.0K
Loans from stockholders	$231.0K		$203.0K
Total liabilities	$5.0M		$18.9M
Common Stock of $0.001 par value (Common Stock): 100,000,000 shares authorized as of December 31, 2025 and 2024; 910,688 and 13,409 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$1.0K		$1.0K
Additional paid-in capital	$151.1M		$119.2M
Receipts on account of shares	$3.5M		$228.0K
Accumulated other comprehensive income	$41.0K		-$8.0K
Accumulated deficit	-$151.8M		-$132.4M
Total stockholders (deficit) equity	$2.8M		-$13.0M		$3.2M
TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY	$7.8M		$5.9M
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	250.0M shares	100.0M shares	100.0M shares
Common stock, shares issued	910.7K shares		13.4K shares
Common stock, shares outstanding	910.7K shares		13.4K shares

Period ending	2025-12-31	2025-01-31	2024-12-31	2024-10-31	2023-12-31
Cash and cash equivalents	$7.4M		$5.6M
Other current assets	$284.0K		$151.0K
Total current assets	$7.7M		$5.8M
Operating lease right-of-use asset, net	$33.0K		$59.0K
Property and equipment, net	$138.0K		$95.0K
Restricted cash			$10.0K
TOTAL ASSETS	$7.8M		$5.9M
Accounts payable	$1.3M		$992.0K
Operating lease liability, current	$28.0K		$26.0K
Promissory notes	$3.2M
Convertible promissory notes			$5.0K
Other current liabilities	$246.0K		$252.0K
Total current liabilities	$4.8M		$1.3M
Derivative financial liabilities	$1.0K		$17.4M	$16.6M
Operating lease liability, non-current	$5.0K		$33.0K
Loans from stockholders	$231.0K		$203.0K
Total liabilities	$5.0M		$18.9M
Common Stock of $0.001 par value (Common Stock): 100,000,000 shares authorized as of December 31, 2025 and 2024; 910,688 and 13,409 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$1.0K		$1.0K
Additional paid-in capital	$151.1M		$119.2M
Receipts on account of shares	$3.5M		$228.0K
Accumulated other comprehensive income	$41.0K		-$8.0K
Accumulated deficit	-$151.8M		-$132.4M
Total stockholders (deficit) equity	$2.8M		-$13.0M		$3.2M
TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY	$7.8M		$5.9M
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	250.0M shares	100.0M shares	100.0M shares
Common stock, shares issued	910.7K shares		13.4K shares
Common stock, shares outstanding	910.7K shares		13.4K shares

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Loss for the year	-$19.4M	-$22.6M
Depreciation	$42.0K	$36.0K
Loss on fixed asset disposal	$16.0K
Equity issuance costs		$1.2M
Stock-based compensation	$211.0K	$173.0K
Issuance of restricted shares as compensation to directors	$122.0K	$306.0K
Amortization of original issue discount related to promissory note	$182.0K
Shares issued to CEO for achieving of IP Agreement milestones		$192.0K
Loss on settlement of liabilities		$4.8M
Loss on equity issuance		$1.9M
Change in fair value of derivative liability	$3.3M	$798.0K
Loss on Series A warrant repurchase	$99.0K
Discount amortization and interest expenses related to promissory notes		$628.0K
Linkage difference on principal of loans from stockholders		$7.0K
Decrease (increase) in other current assets	-$133.0K	$225.0K
Increase in accounts payable	$325.0K	$263.0K
Increase (decrease) in other current liabilities	$17.0K	-$421.0K
Net cash used in operating activities	-$15.2M	-$12.5M
Purchase of property and equipment	-$96.0K	-$104.0K
Net cash used in investment activities	-$96.0K	-$104.0K
Net proceeds received from underwritten U.S. public offering	$10.7M	$8.8M
Proceeds from promissory note, net of original issue discount of $600	$3.0M
Series A warrant repurchase	-$166.0K
Net proceeds from December 2025 private placement transaction	$3.5M
Issuance of promissory notes and detachable warrants through private placement Transaction		$100.0K
Issuance of convertible promissory notes - related parties		$4.0M
Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction		$360.0K
Net proceeds received from underwritten U.S. public offering		$500.0K
Net cash provided by financing activities	$17.0M	$13.7M
Effect of exchange rate changes on cash and cash equivalents	$49.0K	-$24.0K
Change in cash, cash equivalents, and restricted cash	$1.8M	$1.1M
Interest	-$52.0K	-$62.0K
Fair value of equity classified warrants issued in connection with December 2025 private placement	$8.1M
Recognition of right for use asset against a lease liability		$79.0K
Settlement of liabilities with equity		$1.7M
Derivative liability		$35.0K
Conversion of debt into equity		$2.3M

Compare Glucotrack, Inc. with another company

Leadership

Who has led Glucotrack, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Avner Gal2012–2015

Chief financial officer

201520202025

Chief executive officerPaul Goode Apr 24, 2024 to now¹⁰
Chief executive officerAvner Gal Aug 24, 2012 to Mar 13, 2015¹¹
ChairAvner Gal Aug 24, 2012 to Mar 13, 2015¹¹
Chief financial officerPeter C. Wulff Feb 7, 2025 to now¹²
Chief financial officerJames S. Cardwell Oct 18, 2023 to Oct 18, 2023¹³
Chief financial officerSami Sassoun Feb 9, 2017 to Feb 9, 2017¹⁴
Chief financial officerEran Hertz Apr 29, 2014 to Apr 30, 2015¹⁵

Board members and other officers (18)

Interim Chief Strategy OfficerAngela Strand Boydston Jun 7, 2017 to Jun 7, 2017¹⁶
Chief Commercial OfficerDavid Podwalski Jun 28, 2017 to Jun 28, 2017¹⁷
Board memberAndrew K. Balo Mar 28, 2025 to now¹⁸
Board memberLuis Malave Mar 28, 2025 to now¹⁹
Board memberPaul Goode Mar 28, 2025 to now²⁰
Board memberBrendel Victoria Carr Oct 7, 2025 to now²¹
Board memberErin Catherine Carter Sep 11, 2023 to now²²
Board memberAllen Danzig Aug 10, 2022 to now²³
Board memberDrew Sycoff Jul 19, 2019 to now²⁴
Board memberShimon D. Rapps Aug 14, 2019 to Aug 14, 2019²⁵
Board memberMichael Hauck Jun 8, 2017 to Jun 9, 2017²⁶
Board memberAngela Strand Boydston Mar 25, 2016 to Jun 7, 2017²⁷
Board memberLeslie Seff Mar 25, 2016 to Jun 9, 2017²⁸
Board memberRevan Schwartz Nov 15, 2016 to Jun 9, 2017²⁹
Board memberPhilip Darivoff Nov 21, 2016 to Mar 14, 2017³⁰
Board memberIsrael B. Ehrlich Mar 12, 2013 to Mar 12, 2013³¹
Board memberZvi Cohen Aug 24, 2012 to Mar 13, 2015³²
Board memberRobert Fischell Aug 28, 2012 to now³³

Former names

Integrity Applications, Inc.Dec 27, 2010 to Dec 9, 2021³

Timeline

Apr 24, 2024New chief executive Paul Goode becomes CEO¹⁰
Aug 24, 2012New chief executive Avner Gal becomes CEO¹¹
May 18, 2010Founded Glucotrack, Inc. is founded²

Filings

231 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 111 major events, 25 insider forms, 7 large holders, 1 private raises, 66 other. The latest 20:

Oct 14, 2026S-1/A EDGAR
Oct 13, 2026PRE 14A EDGAR
Oct 13, 2026425 EDGAR
Oct 13, 20268-K/A EDGAR
Sep 28, 20268-K EDGAR
Sep 24, 2026424B5 EDGAR
Sep 24, 20268-K EDGAR
Sep 23, 2026425 EDGAR
Sep 23, 20268-K EDGAR
Sep 18, 20268-K EDGAR
Sep 18, 2026S-1 EDGAR
Sep 14, 20268-K EDGAR
Sep 11, 20268-K EDGAR
Sep 9, 20268-K EDGAR
Sep 2, 2026SCHEDULE 13G EDGAR
Aug 28, 20268-K EDGAR
Aug 28, 2026425 EDGAR
Aug 28, 20268-K/A EDGAR
Aug 27, 20268-K EDGAR
Aug 21, 2026DEFA14A EDGAR

The 231 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Apr 22, 2024	SYCOFF DREWDirector	Buy	182,540	$1.26	$230.0K	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

White Lion Capital LLCSCHEDULE 13G, 1 filing Sep 2, 2026³⁴
ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings Feb 17, 2026 to May 15, 2026³⁵
Ikarian Capital, LLCSCHEDULE 13G, 1 filing Feb 17, 2026³⁶
SABBY MANAGEMENT, LLCSCHEDULE 13G/A, 2 filings Jan 3, 2024 to Jan 3, 2025³⁷
Drew SycoffSC 13G, 1 filing Sep 10, 2024³⁸

Money raised

Private offerings the company reported to the SEC on Form D.

Apr 22, 2024Raised $500,000 in a private offering of equity Form D: 9 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARGlucotrack, Inc. filings on SEC EDGAR
2
GLEIFGlucotrack, Inc. LEI record (549300FJ98RZ4G4ULL57)
3
SEC EDGARGlucotrack, Inc. filings on SEC EDGAR
4
SEC EDGARGlucotrack, Inc. annual report, Item 1 (Business)
5
SEC EDGARGlucotrack, Inc. 10-K for fiscal 2019
6
SEC EDGARGlucotrack, Inc. 10-Q for fiscal 2026
7
SEC EDGARGlucotrack, Inc. 10-Q for fiscal 2026
8
SEC EDGARGlucotrack, Inc. 10-K filed 2026-03-30: income statement
9
SEC EDGARGlucotrack, Inc. 10-K for fiscal 2019
10
SEC EDGARPaul Goode, Chief executive officer
11
SEC EDGARAvner Gal, Chief executive officer
12
SEC EDGARPeter C. Wulff, Chief financial officer
13
SEC EDGARJames S. Cardwell, Chief financial officer
14
SEC EDGARSami Sassoun, Chief financial officer
15
SEC EDGAREran Hertz, Chief financial officer
16
SEC EDGARAngela Strand Boydston, Interim Chief Strategy Officer
17
SEC EDGARDavid Podwalski, Chief Commercial Officer
18
SEC EDGARAndrew K. Balo, Board member
19
SEC EDGARLuis Malave, Board member
20
SEC EDGARPaul Goode, Board member
21
SEC EDGARBrendel Victoria Carr, Board member
22
SEC EDGARErin Catherine Carter, Board member
23
SEC EDGARAllen Danzig, Board member
24
SEC EDGARDrew Sycoff, Board member
25
SEC EDGARShimon D. Rapps, Board member
26
SEC EDGARMichael Hauck, Board member
27
SEC EDGARAngela Strand Boydston, Board member
28
SEC EDGARLeslie Seff, Board member
29
SEC EDGARRevan Schwartz, Board member
30
SEC EDGARPhilip Darivoff, Board member
31
SEC EDGARIsrael B. Ehrlich, Board member
32
SEC EDGARZvi Cohen, Board member
33
SEC EDGARRobert Fischell, Board member
34
SEC EDGARWhite Lion Capital LLC SCHEDULE 13G on Glucotrack, Inc.
35
SEC EDGARARMISTICE CAPITAL, LLC SCHEDULE 13G/A on Glucotrack, Inc.
36
SEC EDGARIkarian Capital, LLC SCHEDULE 13G on Glucotrack, Inc.
37
SEC EDGARSABBY MANAGEMENT, LLC SCHEDULE 13G/A on Glucotrack, Inc.
38
SEC EDGARDrew Sycoff SC 13G on Glucotrack, Inc.